Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA's Updated Draft Animal Testing Guidance Clarifies Its Scope

Executive Summary

The US FDA’s guidance document on animal testing for medical devices clarifies the scope of a document issued in 2016.

You may also be interested in...



FDA Focuses On Animal Testing, Trial Endpoints In BPH Device Draft Guidance

Draft guidance from the US FDA updates the agency’s recommendations around research to support new devices for the treatment of prostate enlargement.

US FDA Draft Guidance On Medical Device Animal Studies Is 'Confusing', Says Industry

The US Food and Drug Administration's recent draft guidance on how medical device companies should design and report the results of animal studies is 'confusing', says medtech industry association AdvaMed1,2.

It’s Been Over 1100 Days Since MCIT, Still No TCET In Sight

AdvaMed’s new online clock documents the time since CMS promised to replace MCIT, a program guaranteeing coverage for FDA-cleared breakthrough devices.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT147766

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel